- Home
- ALEC vs ARTV Comparison
ALEC vs ARTV Comparison
Compare ALEC & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- ARTV
- Stock Information
- Founded
- ALEC 2013
- ARTV 2019
- Country
- ALEC United States
- ARTV United States
- Employees
- ALEC N/A
- ARTV N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- ARTV
- Sector
- ALEC Health Care
- ARTV
- Exchange
- ALEC Nasdaq
- ARTV NYSE
- Market Cap
- ALEC 174.3M
- ARTV 186.1M
- IPO Year
- ALEC 2019
- ARTV 2024
- Fundamental
- Price
- ALEC $1.87
- ARTV $3.77
- Analyst Decision
- ALEC Buy
- ARTV Strong Buy
- Analyst Count
- ALEC 6
- ARTV 6
- Target Price
- ALEC $11.75
- ARTV $21.00
- AVG Volume (30 Days)
- ALEC 471.2K
- ARTV 83.1K
- Earning Date
- ALEC 02-26-2025
- ARTV 03-04-2025
- Dividend Yield
- ALEC N/A
- ARTV N/A
- EPS Growth
- ALEC N/A
- ARTV N/A
- EPS
- ALEC N/A
- ARTV N/A
- Revenue
- ALEC $61,508,000.00
- ARTV $2,601,000.00
- Revenue This Year
- ALEC N/A
- ARTV N/A
- Revenue Next Year
- ALEC $0.12
- ARTV N/A
- P/E Ratio
- ALEC N/A
- ARTV N/A
- Revenue Growth
- ALEC N/A
- ARTV N/A
- 52 Week Low
- ALEC $1.55
- ARTV $3.37
- 52 Week High
- ALEC $7.58
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- ALEC 54.66
- ARTV N/A
- Support Level
- ALEC $1.71
- ARTV N/A
- Resistance Level
- ALEC $1.86
- ARTV N/A
- Average True Range (ATR)
- ALEC 0.10
- ARTV 0.00
- MACD
- ALEC 0.04
- ARTV 0.00
- Stochastic Oscillator
- ALEC 84.21
- ARTV 0.00
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.